



Optimapharm confirms Mirna Šenjug Novak as Group CFO

Optimapharm, a leading, mid-sized, full-service CRO (Contract Research Organization) across Europe and North America, is excited to announce the promotion of Mirna Šenjug Novak as Group Chief Financial Officer (CFO), effective February 2023

Mirna Šenjug Novak is a finance professional with over 15 years of experience in the pharmaceutical and banking industry, M&A, and integrations.

In 2012, she became a member of the Optimapharm team and proceeded to establish procedures and systems within the company's Finance Department. She was involved in various DD processes, on the buyer side, and led several post-acquisition integrations. Several IT implementations on the customer side, such as DMS, CTMS, and accounting software were successfully delivered under Mirna's leadership. Mirna took over the Group Chief Financial Officer (CFO) role, succeeding in her previous position as Vice President of Finance.

"I have proudly been a part of Optimapharm for more than 10 years and feel honored to be able to serve the company in my new position as a CFO. This team has already done amazing things and I'm excited to contribute my deep understanding of the company's history and operations and my passion for driving growth and innovation to ensure our continued success." said Mirna Šenjug Novak, Group Chief Financial Officer.

In her new role Mirna becomes Member of the Management Board, having demonstrated exceptional leadership and financial expertise as a key finance team member. Mirna holds an MA in Economics (major in Finance) from the University of Zagreb, Croatia, and has completed the CFA program at the CFA Institute.

About Optimapharm

Optimapharm is a leading, mid-sized, full-service CRO across Europe and North America focused on our People, consistent quality delivery to our Clients, and supporting the development of new therapies to improve and save Patients' lives. The company provides successful tailor-made clinical research solutions to Biotech, Pharma, and Medical Device companies in 41 countries.

With 27 strategically located offices, Optimapharm is giving unrivaled access to Patients and Investigators in all countries in Europe and North America, with a total population of over 900 million people. Optimapharm conducts phase I – IV studies in all therapeutic areas, specifically focusing on Oncology/Haemato-oncology, Cardio-metabolic, CNS, Respiratory, GI&GU, Immunology/Rheumatology, and in complex medical device studies. With very strong operational teams, Optimapharm has a reputation for excellence delivery in all projects, including rescue studies.

Optimapharm - We Deliver on Your Promises

Web site: <https://optimapharm.eu/>